MBIO (Mustang Bio) Bathi resik saben saham (EPS TTM)

Mustang Bio, Inc. (MBIO) is developing a closed-loop oncology system based on CRISPR and CAR-T with in-house manufacturing. The change in rolling net income per share visualizes the effectiveness of this approach, where -0.52 reflects the latest value of the metric. Business profitability remains independent of economic cycles, relying instead on demand within the genetics sector. The US financial base and the absence of geopolitical risks guarantee the security of the patents.
Rincian metrik lan analitis perusahaan Mustang Bio, Inc. (MBIO)

The stability of Mustang Bio, Inc. (MBIO) patents within the US oncology sector minimizes external risks. By analyzing the rolling earnings per share (EPS) indicator, investors can discern the actual capitalization efficiency of these assets. This metric aggregates annual net income, dividing it by the number of shares to identify the business's true momentum. The systematic growth of the trend line confirms a fundamental margin of safety, although sharp spikes warrant caution due to the risk of subsequent capital revaluation.